LakeShore Biopharma Co., Ltd.
LSBPW
NASDAQ Global Market0.01
USD
- -
- -
CIK
0001946399
Return %
Stock
S&P500
1Y
-82.09
26.84
3Y
-90.51
77.03
5Y
-90.51
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Wang Xu
- Full Time Employees
- 758
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building No. 2 Beijing People's Republic of China 102629
- CIK
- 0001946399
- Website
- lakeshorebio.com
- Similar Companies
- Business
- LakeShore Biopharma Co., Ltd. is a global biopharmaceutical entity focused on the discovery, development, production, and commercialization of cutting-edge vaccines and therapeutic biologics for battling infectious diseases and various cancers. The company leverages its proprietary PIKA immunomodulating technology platform, which activates immune signaling pathways, to advance a diverse pipeline of products. This includes an innovative PIKA rabies vaccine currently undergoing a Biologics License Application submission in Pakistan and holding Orphan Drug Designation from the U.S. FDA, along with a PIKA recombinant COVID-19 vaccine and PIKA YS-ON-001, an immunotherapy for cancer that completed its Phase I trial in 2023. The company also offers its established YSJA™ rabies vaccine, a market leader in China, which recently saw the launch of a novel, safer packaging solution in April 2025, and is progressing with a Phase III trial for a simplified dosing regimen. Operating across China, the United States, Singapore, the United Arab Emirates, and the Philippines, LakeShore Biopharma was originally established in 1994. The company underwent a legal name change from YS Biopharma Co., Ltd. to LakeShore Biopharma Co., Ltd. in May 2024 to better reflect its international brand and market reach. In recent developments, LakeShore Biopharma has transitioned its trading to the OTC Pink Open Market in September 2025, following a delisting from Nasdaq due to non-compliance with listing rules, and is also evaluating a preliminary non-binding proposal to be acquired.